

ANNUAL REPORT AND ACCOUNTS

2021-2022



**THE
BRAIN
TUMOUR
CHARITY**



CHAIR'S REPORT

First of all, may I start with a heartfelt thank you for standing with us over the past year.

This year has been one requiring resilience from us all – a year where the needs of families affected by a brain tumour have only been heightened. NHS and community resources are at full stretch, people are waiting longer to receive urgently needed care and valuable emotional support is in high demand.

Our response has been to turn to The Charity's greatest resource – you!

By joining together as a stronger, collective voice we've been able to create meaningful change, despite the challenging environment. Our voice is made of many remarkable people making individual differences. Some of you are highlighted in this Report – our inspiring new cohort of Young Ambassadors, our relentless founding Trustees and our indefatigable Head of Strategy – but standing with them are countless others similarly passionate about improving the outlook for families affected by brain tumours.

Despite the lasting effects of the pandemic and now the emerging cost of living crisis, the overwhelming generosity and incredible drive of the community means we've been able to meet the increased demand for our support services, continue to push for the best care everywhere and also begin funding new research projects again and start rebuilding our team.

This progress has not been easy. On behalf of my fellow Trustees, I would like to thank The Charity's leadership team – with particular thanks to our Interim CEO and Chief Scientific Officer, Dr David Jenkinson – for navigating us through this critical and challenging period. As David returns to his research role and we resume the search for a permanent CEO, I'm delighted and most grateful that two of our long-standing and highly experienced Trustees,

Graham Norton and Graham Lindsay, have stood down from the Board and stepped forward to give the leadership team their support as Interim CEO and Interim Deputy CEO, respectively.

We were saddened to hear of the death of The Charity's President Professor Sir Colin Blakemore in late June 2022. In 2011, Colin agreed to join Brain Tumour UK, one of the charities that merged to form The Brain Tumour Charity, and continued his work with The Charity after the merger. He always gave all his energy to the projects he was involved in and was particularly impactful in the early days of BRIAN, serving as the Chair of the Patient Mandate Group, steering the development of the app and access to data. Our thoughts are with his family and those who knew him.

Above all though, I want to thank you for standing alongside us through these difficult times, whether you're a fundraiser, a donor, a change maker or helping us defeat brain tumours in the lab or clinic.

Our goals remain ambitious – to double survival and halve the harm that brain tumours have on quality of life. Our growing union with you, our community, takes us closer towards these goals and enriches everything we do and I'm excited we're using this as a springboard to a better future by creating our next strategy together – *Beyond Brain Tumours*. It's not too late to join in and I look forward to continuing this work with you.

In the meantime, on behalf of all those affected, thank you again for the vital role you have played in helping us meet the challenges past, present and future.

I wish you a peaceful and hopeful year.

Jack Morris CBE
Chair of Trustees

CONTENTS

Report of the Trustees	3
a. Strategic Report	12
b. Statement of the Trustees' responsibilities	38
Independent auditor's report	39
Statement of financial activities	42
Balance sheet	43
Cash flow statement	44

YOUNG AMBASSADORS

In 2021, we were delighted to welcome our fourth cohort of Young Ambassadors to The Charity.

Our Young Ambassadors are an integral part of The Brain Tumour Charity, working tirelessly to raise awareness and create a better future for everyone affected by a brain tumour.

By sharing their deeply personal experiences of a brain tumour, they help us to better connect with those who come to us for support, especially other young adults, and help us encourage new supporters and Government officials to join our voices for change.

Our Young Ambassadors have also contributed their time and expertise by getting involved as we develop our new organisational strategy – *Beyond Brain Tumours*.

We consider ourselves fortunate to have their enthusiasm and deep commitment. We're always in awe of how they've reacted to the hardest life experiences by wanting to give their time and put other people first. We're eternally grateful for their involvement.



“

Losing my Mum to a brain tumour, at such a young age, has been the hardest thing I have ever had to face. I want to be a Young Ambassador to help provide support to others who have been through or are going through something similar. I want to not only help raise awareness of brain tumours, but also help to raise awareness of the effects that it has on the loved ones. I felt that I lost my Mum long before she passed, as her tumour changed her in many ways. I wish I had opened up more on how this affected me, so I would love to be a support to others going through this struggle.

Amy

“

My Dad unfortunately lost his 18-month battle with a grade 4 Glioblastoma last July. I witnessed first-hand just how debilitating this illness was for Dad, but in many ways, it was just as debilitating for my Mum, sisters and me too. Whilst it would be far too easy for me to dwell in bitterness, frustration and disappointment, I know that my Dad would not want this for me. Being a Young Ambassador means that I'm able to direct my energy into something positive whilst keeping the memory of the greatest man I've ever known alive.

Kajal

“

I wanted to become a Young Ambassador because I would like to become more confident in myself and also become more confident talking about my tumour and how it affects me. I would like to help The Charity as it has helped me so much. I would also like to campaign for better and faster treatment for people with low grade tumours like mine.

Kate

“

Being diagnosed with a brain tumour can be terrifying. However, having experienced the support The Brain Tumour Charity have to offer, I want to help them make a difference to others' lives in my role as a Young Ambassador.

Jazz

“

I became a Young Ambassador to be there for people and their loved ones who have been impacted by a brain tumour, as well as to help raise awareness for brain tumours (especially in the UK) because I know it is a problem, through personal experience. I believe my story has the potential to make an impact and I would like to get involved in campaigns that involve speaking to policy makers and the media about how to tackle brain tumour awareness and diagnosis.

Rhudi

“

I'm excited to become a Young Ambassador to support other young people who are affected by brain tumours. The research and support available now, compared to when I had my treatment ten years ago, is phenomenal, and I'm really looking forward to engaging with other young people going through similar experiences. I'm excited to get involved in lots of fundraising and awareness events and help raise the profile of research into brain tumours.

Rebecca



Meet our Young Ambassadors



CEO'S REPORT

I would like to second Jack's thanks for your unwavering support during another challenging year.

We're all here for one simple reason – to improve the lives of the estimated 88,000¹ people living with a brain tumour in the UK. Over 12,000 more people face a brain tumour diagnosis each year and, despite momentum gathering from the threefold increase in research funding over the past decade², just 12% of those people survive more than five years (compared with an average across all cancers of 54%).³

It's important to remember that these aren't just numbers. The recent death of Tom Parker, less than 18 months after his diagnosis of a glioblastoma, shone a harsh light on the brutal reality behind these statistics. We know Tom's death hit the community hard as his story is reflective of so many of your experiences – demonstrating how far we still have left to go.

Highlights have included

- achieving record annual income of £11.5m (a growth of 38% from 2020/21) and reaching the incredible milestone of raising a total of £100m since The Charity was founded 25 years ago
- making significant improvements to our BRIAN app for its 7,000+ users, including making it easier for researchers to use BRIAN's data to accelerate a cure
- embedding our Improving Brain Tumour Care surveys in many neuroscience centres in the UK, helping to hold treatment centres accountable for gaps in care

- airing our first ever TV advert across the UK
- returning to holding in-person events, much to the relief of the community and our Events team.

Perhaps most exciting of all, we launched our forward-thinking new research strategy, *Accelerating a Cure*. It's impossible not to read this and be excited about our direction of travel.

And we still have so much ahead of us to look forward to! As I write, we're launching our long-awaited *Better Safe Than Tumour* campaign to raise awareness of common brain tumour signs and symptoms, building on the success of our *Headsmart* campaign.

We're also deep into the process of engaging our UK and wider community in co-creating our next organisational strategy, *Beyond Brain Tumours*. This is a natural evolution of our focus on individuals, their needs and how we can move further, faster when we join together – but it feels more like a revolution! We've already brought together over 1,000 people from across the brain tumour community and there's still time for you to join us.

It's been a busy year for The Charity, regrouping after the pandemic and rebuilding our foundations stronger than ever. With you at our side, we're ready to face whatever the future holds, resolute in our aim to double survival and halve the harm that brain tumours have on quality of life.

Thank you for making a difference and please continue to add your voice for change.

Graham Norton
Interim CEO

OUR GOALS AND VALUES

OUR GOALS

Our vision is for a world where brain tumours are defeated and our goals are our blueprint for getting there. Simply put, if something doesn't help us achieve one of these goals, we know that it's not the right direction for us.

We've set ourselves goals that are unashamedly ambitious as this is the only way we'll see a real and last difference. We want to:

- double survival in the UK
- halve the harm that brain tumours have on quality of life in the UK

OUR VALUES

Our values underpin everything that we do, they define what we believe and guide our actions every day.

The way we work is always:

PIONEERING

We're relentless and courageous in the pursuit of our vision, seeking new ways to make a difference.

PASSIONATE

People are at the heart of everything we do. We're passionate about finding a cure and ensuring everyone affected by a brain tumour has the highest quality of life and chance of survival.

COLLABORATIVE

We'll only achieve our vision by building networks, partnerships and a strong community of people affected by a brain tumour. We collaborate and value everyone's contribution.

SMART

We're focused and intelligent in our approach to defeating brain tumours.

for every £1 we spent in 2021/22,

82p

was spent on charitable activities

for every £1 we spent in 2021/22 more than,

50%+

was spent on research

¹ TBTC estimate 2019, based on published survival rates and incidence from cancer registry data for England, Northern Ireland, Wales and Scotland.

² NCRI tables plus TBTC research spend (from our Annual reports). NCRI data: Cancer Research Spend Data Package 2019 Final [Internet]. Accessed 2020. Available from: <http://www.ncri.org.uk/what-we-do/research-database/>

³ Cancer Research UK, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-tumours/incidence>, Accessed April 2022

CLARE NORMAND, OUR HEAD OF STRATEGY, HONoured WITH OBE

Clare has been at the heart of The Charity since she joined the team in 2012 and runs a supporter group, The Alec Normand Fund, in memory of her son.



Clare's amazing work was recognised in the 2021 New Year's Honours list when she was awarded an OBE for her services to brain tumour charities. She's been at the heart of The Charity leadership team since 2012, leading on our strategy and making sure we hold ourselves accountable for progress and impact.

Clare began supporting The Samantha Dickson Brain Tumour Trust (now The Brain Tumour Charity) in 2007, after her nine-year-old son, Alec, was diagnosed with an inoperable brain tumour.

Alec tragically passed away just ten months after his diagnosis.

Since then, Clare, her husband Christopher, and their two other children – Oliver and Ursie – have been responsible for raising almost £700,000 for The Alec Normand Fund.

Clare was the driving force behind the ambitious *Defeating Brain Tumours* strategy that saw The Charity invest £38m towards research into brain tumours between 2015 and 2020 – nearly double our target of investing £20m during that period.

Always mindful that our greatest resource is the passionate brain tumour community, Clare masterminded our transitional *Leaning In* strategy that allowed The Charity to respond to the COVID-19 crisis by drawing on our strengths and leaning into the community to maximise the impact we can have together.

Now, Clare is making sure our next strategy, *Beyond Brain Tumours*, is truly led by the needs of the community through a process called co-creation – something that very few charities have attempted at this scale. Over 1,000 people have already contributed their insight, time and work to the new strategy. This diverse mix of people includes those personally affected by the disease, brain tumour researchers, healthcare professionals and other charities that are committed to defeating brain tumours.

Clare said, "Singling me out for an OBE must be put in context: my whole family has shared the loss of Alec and has given me the space over the last few years to pursue the promise he asked of us to stop this happening to others; there are countless families that have been devastated by the effects of a brain tumour; and there are hundreds of other people working tirelessly to find a cure for brain tumours.

"In accepting this honour, I consider myself to be a representative of all of them, and I hope this public recognition of our combined efforts will inspire further support."

In response to the news, our CEO said: "Clare has been instrumental in developing our strategy, shaping us into the world-leading charity that we are today.

"Her exceptional talent, drive and compassion, going above and beyond in everything she does, has played a key part in the growth in income and impact of The Brain Tumour Charity over the years. She continues to be a beacon of support and inspiration to so many in our community affected by a brain tumour diagnosis.

"I have worked with Clare for almost six years and I see her as the beating heart of The Charity. She is the very embodiment of our values, being supremely passionate, pioneering, smart and collaborative in everything she does. She brings a real inventiveness to our work combined with high levels of intellectual rigour, all delivered with her overwhelming generosity of spirit and personality."

David Jenkinson
Chief Scientific Officer,
past Interim CEO
(Jan 2021 – Jan 2022).

“

Her exceptional talent, drive and compassion, going above and beyond in everything she does, has played a key part in the growth in income and impact of The Brain Tumour Charity over the years.


OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

- relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system
- relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support
- advancing the education of the public in all areas relating to tumours of the brain and central nervous system

PUBLIC BENEFIT STATEMENT

The Trustees have considered the Charity Commission’s general guidance on public benefit and have taken it into account when reviewing The Charity’s aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.



DEFEATING BRAIN TUMOURS: LEANING IN

COVID-19 had a major impact on those with brain tumours, on brain tumour care, on the pace of research and on our own resources.

In order to support the community’s heightened needs through the pandemic and beyond, we developed a short-term strategy for 2021/22 that empowered us to do more with fewer resources available by leaning into our strengths, becoming a more flexible organisation and involving the community at every opportunity.

To do this, as well as make sure we’re in the best possible position to accelerate a cure in a much-changed post-pandemic world, this strategy was built around four pillars of work:

Power of Data

We’ll harness the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

Best Care Everywhere

We’ll drive the best care everywhere across the UK, empowering the community to access high levels of care no matter where they’re located and helping treatment centres reach the highest possible standards.

Voices for Change

We’ll empower everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they’re fundraisers or change makers.

Make it Count

We’ll use our resources, skills and technology efficiently and effectively to make sure we maximise our impact with minimal resources.

THE GIFT OF TIME



In December 2021, The Charity launched our first ever TV advert based on the powerful and emotive short film created by our partner Runningman Two for our Winter Appeal.

The film was based on the idea that the best gift that families affected by a brain tumour could possibly receive is the gift of more time together.

Tom Buckley, a producer at Runningman Two, drew on his own experiences of a loved one being diagnosed with a brain tumour to bring the idea to life in a way that deeply resonated with the community.

The Winter Appeal was a huge success and as well as increasing the reach of the brand by appearing on TV screens across the UK over the festive period, we managed to raise over £225,000!



Being someone who is part of a family that has been directly affected by a brain tumour diagnosis at Christmas time; this campaign was close to me on a personal level.

I hate the idea of anyone else having to go through what we have in the Buckley family – I wanted to raise as much money as possible for this amazing cause.

Tom Buckley
Producer at Runningman Two



STRATEGIC REPORT

THE POWER OF DATA

We'll harness the power of data to conquer our goals of doubling survival and halving the harm caused by brain tumours.

Remaining evidence-led, we'll gather and analyse data and knowledge from reputable sources, including our pioneering BRIAN app and databank; experts by experience and those personally affected; government sources; research publications and other reliable sources.

We'll use these insights to tackle inequality, inform change and help those affected by a brain tumour make the right choices.

HIGHLIGHTS OF 2021/22

TAKING BRIAN TO THE NEXT LEVEL

Our BRIAN (the Brain tumouR Information and Analysis Network) project continues to go from strength to strength. We smashed our target of having 5,000 registered BRIAN users by the end of 2021/22, nearly doubling the number of BRIAN users from 3,800 to 7,200 users.

We're determined that the development of our BRIAN app will always be led by those who use it, so we regularly meet with BRIAN users and Young Ambassadors to get their thoughts – as well as running feedback surveys so every user can have a voice.

This led to an overhaul of the mobile app's interface in 2022, resulting in a new and improved user experience. We also built, tested and released two new features, the Seizure Tracker and Clinical Trial Link, that help better support the community and make it easier for researchers to collect the data they need for studies.

The Seizure Tracker allows users to record the type, time and duration of their seizures, which can then be shared with their clinicians.

7,200

registered BRIAN users

The Clinical Trial Link allows researchers to collect data from consenting clinical trial participants through BRIAN. This makes it easier for researchers to securely collect data, which is ring-fenced from the general data analysis in BRIAN until the trial has been completed and the results have been reported.

As part of the project, we received a refresh of data from both NHS Digital and Public Health England. In combination with our access to data from Scotland, Wales and Northern Ireland, this has allowed us to increase the number of insights available from 8 to 35. This is particularly significant as it now empowers the community in the devolved nations to understand their own treatment and care in relation to others in their home country.

IMPROVING SAFE AND SECURE ACCESS TO DATA

Making it easier for researchers to safely and securely access the data collected by BRIAN is key to our strategy for defeating brain tumours.

To help speed up the process of data access and make it easier for researchers to find the data they need we've been working with Health Data Research UK (HDRUK) to register BRIAN on their Innovation Gateway. As part of this process, we compiled the metadata in BRIAN to allow researchers to quickly understand what data is available and this was given the gold standard by HDRUK. We've also begun to explore moving access requests to the HDRUK platform, which will allow us to link into the national data usage register it curates and help ensure transparency around how the data is used.

To further enhance this process, we've explored the use of a Trusted Research Environment (TRE). A TRE makes it possible to give researchers access to the parts of the data they need to conduct their analyses without sharing the entire BRIAN dataset with them. This will significantly enhance the security of the data and

should reduce delays in granting access to researchers. After a rigorous selection process, we're now working to integrate our chosen TRE with BRIAN and transfer the data to it.

Ensuring the security of both the app and the data stored within BRIAN is a top priority for The Charity and in the past year the app was reviewed by ORCHA – the global leader in providing access to trusted digital health.

After being given a massive 92% rating, BRIAN is now in the top six apps in ORCHA's app library and is its top-rated cancer app.

92%

ORCHA rating for BRIAN

NHS Digital also performed its annual audit of our processes and data security. BRIAN was once again rated in the top category as being a low risk to the security of the NHS data or improper usage.



FUNDING NEW RESEARCH

The huge financial impact of the pandemic hit The Charity hard and we had to make the difficult decision to pause funding new research to make sure we were able to protect the projects we'd already pledged to support.

This year, once it became clear that income was recovering, we were excited to be able to return to new grant funding for research.

We progressed three grant calls during the year, with our Future Leaders programme opening for the third cohort of applicants. We look forward to selecting the successful applicants later in 2022.

We also began undertaking a review of our funding to the Everest Centre for Paediatric Low Grade Glioma as it nears its five-year anniversary. The work from the centre was integral to the new classification of brain tumours, released by the World Health Organisation in December 2021.

This classification includes the use of methylation, small marks on the DNA of cells telling them which genes to use and which to switch off, to assist pathologists. The Everest team pioneered this technology and made major contributions to the new system, along with several of our other funded researchers.

LAUNCHING OUR NEW RESEARCH STRATEGY

In late 2021, to help facilitate our return to traditional grant funding, we published our new research strategy - *Accelerating a Cure*.

Like everything we do, the development of *Accelerating a Cure* was led by the community. We consulted with people personally affected by brain tumours, leading researchers in the field and innovators from beyond the sector.

While groundwork for the strategy had mostly been completed pre-pandemic, we were able to take everything we've learned from operating through the COVID-19 crisis and use that knowledge to ensure *Accelerating a Cure* would be successful in the much-changed post-pandemic research landscape.

Accelerating a Cure builds on the incredible progress we made during our previous research strategy, *A Cure Can't Wait*, while identifying areas that need extra work to improve. **Key to this will be kick-starting translational research to ensure our world-class discovery research is used to develop new treatments for those living with a brain tumour.**

The community's voice will play a central role in our new approach to research that aims to enhance quality of life. We plan on working closely with the Tessa Jowell Brain Cancer Mission to validate areas of best practice around the neuroscience centres in the UK and provide evidence to ensure those practices are adopted widely.

 You can read more about [Accelerating a Cure](#) here.

“

Thank you, on behalf of all of us touched by this brutal disease. We're proud of having shaped the ambition and direction of *Accelerating a Cure* as a springboard for improving the future for those with brain tumours. Please get involved and help us go further, faster!

The Involvement Network

CELEBRATING OUR FOUNDERS

In November 2021, we welcomed our Founders, Neil and Angela Dickson MBE, to our new offices to celebrate everything that's been achieved in the 25 years since they founded The Samantha Dickson Research Trust.

Neil and Angela founded The Trust, which would later become known as The Brain Tumour Charity, in memory of their daughter Samantha, who passed away from a rare form of glioma when she was just 16.

"For everything that Neil and Angela have done over the 25 years, for everything they've done for the charity, our sincere and heartfelt thanks. They've helped us to make an impact to change the way people are being treated, being supported and an impact to change the future for everyone affected by a brain tumour diagnosis."

Dr David Jenkinson
Chief Scientific Officer, past Interim CEO
(Jan 2021 – Jan 2022)

"When we first set up The Charity, initially in our daughter's name, we never thought we would have achieved so much, and part of this is the fact that so little was being done for this disease. Brain tumours reduce average life expectancy by 27 years – by far the highest burden of any cancer or major disease.

"We have helped extend average life expectancy by 15 months (5%) for those with brain cancer, amongst the highest increase of any major disease or cancer since 2010."

Angela Dickson MBE
Founder



BEST CARE EVERYWHERE

We'll continue to drive the best care across all treatment centres in the UK to achieve our goal of everybody receiving consistently excellent care – no matter where they live or what kind of tumour they're diagnosed with.

By empowering the community to share their experiences of receiving treatment and care, we ensure the patient voice plays a key role in levelling up care. By working directly with healthcare professionals and the Tessa Jowell Brain Cancer Mission, we provide treatment centres with the tools they need to improve standards.

And, where there are gaps in care that can't currently be filled, we'll strive to provide services that ensure the community have their needs met.

HIGHLIGHTS OF 2021/22

CONTINUING TO MEET THE GROWING DEMAND FOR OUR SUPPORT SERVICES

Throughout 2021/22, we saw a continued increase in demand for our support services. Our Support and Information Line delivered 27% more support than the previous year and we supported 11,300 people on a one-to-one basis – up 9% on the previous year. We also had around 1.3m support seekers visiting our website for help this year.

1.3M

support seekers visiting our website for help

Our Online Brain Tumour Support Groups grew 21% this year to over 24,000 members. These groups are invaluable because they're a safe space to ask questions and receive advice at all hours of the day – as well as empowering people to support each other. They also help create a much-needed sense of community, connecting people affected by a brain tumour with others who share their experiences at a time when they can often feel most isolated and alone.

11,300

people supported one-to-one

It's only thanks to the incredible support we receive from our volunteer community that we've been able to manage this increased demand for our services. Well-trained and fully supported volunteers now triage every call to our Support and Information Line, help moderate our thriving Online Brain Tumour Support Groups and work collaboratively with us to create resources for the community.

24,000

24,000+ members of our Online Brain Tumour Support Groups

AMPLIFYING THE COMMUNITY'S VOICE TO MAKE MEANINGFUL CHANGES IN CARE

We've continued to empower the community to have their voices heard through our Improving Brain Tumour Care surveys and in September 2021, we began the latest round of analysis on just under 1,500 completed surveys.

Thanks to the community sharing where they were receiving best care and where there were gaps, we were able to send patient feedback reports to 25 of the 30 adult neuroscience centres in the UK to help those centres improve treatment and care.

25/30

neuroscience centres received feedback reports on their standard of care

These surveys are also the patient voice in the assessment of neuroscience centres for Tessa Jowell Centres of Excellence accreditation and 17 of the 30 adult neuroscience centres in the UK are now recognised as Centres of Excellence.

This is making a tangible difference to care, with many centres adding Clinical Nurse Specialist and Allied Health Professional posts in response to gaps identified in the Improving Brain Tumour Care surveys. Some centres have also been able to make successful business cases for other improvements using the evidence of what other centres have in place and what the community says is a shortfall.

17/30

neuroscience centres recognised as Centres of Excellence

Before COVID, we were funding CNS low grade posts to improve provision, but this patient and clinical-led assessment of excellence is proving to be a far more effective, scalable and sustainable way of bringing new investment and making change.

The Improving Brain Tumour Care surveys have also identified huge differences in people's experiences depending on where they received treatment from and whether they have a high grade or low grade tumour, as well as gaps in care across the UK.

This is unacceptable and we're working to close those gaps by sharing best practice across the Tessa Jowell Centres of Excellence, as well as with the neuroscience centres who haven't yet achieved that accreditation – as well as developing solutions to fix problems that continue to persist.

We submitted patient-led evidence to eight policy consultations across the UK, ensuring that better access to a CNS or key worker was recognised by the National Institute for Health and Care Excellence (NICE) as a priority area for improvement in its new Quality Standard on brain tumours in England.

We also presented key evidence from our Improving Brain Tumour Care surveys in Parliament to the All-Party Parliamentary Group on Brain Tumours. This ensured the findings from the survey were included in the Health and Social Care Select Committee's Report on progress towards the Government's cancer ambitions.

SUPPORTING HEALTHCARE PROFESSIONALS

As well as highlighting the gaps in care, we're also helping to close them with practical solutions.

In 2021/22 we trained 6,141 optical professionals to spot the signs and symptoms of a brain tumour more effectively. As we launch our *Better Safe than Tumour* campaign to drive earlier diagnosis, we'll be actively growing our healthcare engagement work to support this aim of reducing diagnosis times for adults and children.

6,141

optical professionals trained

Our BRIAN app is helping healthcare professionals offer more proactive care to patients and is now embedded in the pathway of four neuroscience centres. We've already heard stories of Clinical Nurse Specialist teams who prevented an unplanned admission because they contacted a patient when they saw their well-being scores dropping.

We were also made aware of a case where an individual was using BRIAN to record his seizures following treatment for a glioblastoma, after being introduced to the app by his Clinical Nurse Specialist. It was only via the app that this individual was identifying "brain fog" lasting for a few minutes and after showing his neurologist, his anti-epileptic medication was increased and no further episodes were recorded.

A new BRIAN feature aimed towards closing gaps in care has been in development this year, after consultation with our community of healthcare professionals. The My Support Plan feature is a Holistic Needs Assessment (HNA) and support planning tool, which directly answers the lack of HNA provision identified through the Improving Brain Tumour Care surveys as a gap in care that exists across the UK.



AN AWARD-WINNING PARTNERSHIP



We were delighted to accept Marketing Partnership of the Year at the Third Sector Business Charity Awards for an innovative project built with the help of 650 hours of time donated by the team at Salesforce Marketing Cloud for Nonprofits.

Marketing Cloud led a project to redefine our supporter experience, transforming how we understand and talk to our supporters. The project included data analysis, collaborative workshops and training sessions - ultimately delivering a new audience segmentation model and pilot campaign - featuring Young Ambassador Jeremy Daubeney and his Tour de Full English cycle challenge around Britain!

The campaign was a great success, but this is just the start! The true value of the partnership will be many times greater as we use the new approach to better communicate with all our supporters - improving their experiences, bringing them into the community and deepening their long term relationship with The Charity.

"The Team at Salesforce.org have been absolutely awesome; they kept us focused and helped us maximise the benefits of Marketing Cloud.

"We wanted to build a test-and-learn culture with a common language and they gave us that with a blueprint for future activity.

"We wanted to create and launch a new campaign and with their help, guidance and encouragement, we did.

"The team were with us every step of the way with practical advice, brilliant workshops, focused team training and advice on how to optimise our model.

"I never believed we could build something so creative and so practical in such a short space of time - we cannot thank them enough!"

Gina Almond
Director of Fundraising and Marketing

VOICES FOR CHANGE

We'll galvanise those who have the motivation, but not necessarily the means, to become a voice for change by giving the community the resources, knowledge, platforms and tools, they need to engage and help tackle the inequalities faced by those affected by brain tumours.

HIGHLIGHTS OF 2021/22

ACHIEVING RECORD-BREAKING INCOME

2021/22 was wildly successful from a fundraising perspective, as we managed to bring in an incredible £11.5m. This was The Charity's highest ever yearly income and an increase of 38% on the previous year. Without the financial support of our generous and dedicated community we couldn't continue our vital work. We'd especially like to shout out our major donors, who contributed a remarkable £2m to our record-breaking income.

£11.5M

raised in 2021/22

Unsurprisingly, our income from events suffered hugely during the pandemic, but in 2021/22 we returned to running in-person events, as well as utilising hybrid events to huge success. COVID restrictions meant we couldn't run a full calendar of events but our amazing supporters helped us bounce back and many events performed better than previous years.

A real highlight was the Virgin Money London Marathon in October 2021 – our most successful yet! 100 of our supporters laced

up their running shoes and took to the streets to support The Charity, raising an astonishing £435,169 and covering a whopping 2,620 miles.

We also celebrated two major milestones that were achieved this year by organisations who've been long-term supporters of The Charity and have played key roles in our success.

For 10 years, our corporate partner Bluecube Technology Solutions have been making sure our team stays connected to each other and the community. This year, the technical expertise they provide, combined with tremendous support for our matched-funding appeals, has surpassed a whopping £1m.

We can't possibly overemphasise how important their support has been. By making sure we have access to high-quality, reliable, efficient and safe IT systems and services, they've empowered The Charity to grow and increase the scale of our work. This was especially important during the pandemic, allowing us to seamlessly transition to working from home and continue to support the community.

Since 2014, ex-England Rugby Captain Lewis Moody has gone to some extreme lengths to tackle brain tumours – including cycling through rainforests and trekking to both the North and South Poles. In 2021/22, the World Cup winner achieved yet another historic milestone as The Lewis Moody Foundation celebrated raising a total of £2 million to help defeat brain tumours!

Lewis and his wife, Annie, were inspired to launch The Lewis Moody Foundation after they met the incredible Joss Rowley Stark in 2012. Sadly, Joss passed away in 2013 after a battle with a rare form of cancer and The Foundation was created in 2014 in his memory.

We're so proud of what Lewis, Annie and their amazing supporters have been able to achieve in raising funds for pioneering research and vital support services facilitated by The Charity.

FORGING AN AWARD-WINNING PARTNERSHIP

For several months and 650 hours of gifted time, The Charity worked with Salesforce Marketing Cloud for Nonprofits to create an audience segmentation model and automated journeys for our supporters to ensure they have the best possible experience.

The rich and moving content was built with one of our Young Ambassadors, Jeremy Daubeney, and resulted in an increase in donations, an increase in engagement with our content and a doubling in the average gift.

This is a major shift in digital delivery for The Charity as we move from product-led campaigns to audience led-campaigns. This amazing project also resulted in an award for Marketing Partnership of the Year at the *Third Sector Business Charity Awards*.

LIVING UP TO OUR VALUES AS PIONEERS

With the help and support of the community, we were also able to try some exciting new things this year.

In December 2021, we launched our first ever TV advert in support of our Christmas appeal. The advert was based on the powerful and emotive *The Gift of Time* animation that was gifted to us by our partner Runningman Two. It appeared across a wide range of TV channels during the holidays and was extremely well received.

As well as giving us the opportunity to dip our toes into the exciting waters of advertising on TV for the first time, it also enabled us to enhance our ability to receive donations via SMS.

After consultation with our Supporter Groups and family-led charities, we also launched our CREATE design platform that empowers the community to produce their own fundraising and awareness materials using our design assets.

Throughout 2021/22 we also developed two new campaigns that will launch in the summer of 2022, our Win Big Weekly Lottery and our long-awaited signs and symptoms campaign – *Better Safe Than Tumour*.

Better Safe than Tumour will build on our successful Headsmart campaign and expand upon it to cover adult signs and symptoms too. We look forward to the community seeing this new campaign and helping us spread it far and wide across all channels.



CELEBRATING OUR CELEBRITY SUPPORTERS

We owe our celebrity supporters a great deal of thanks for helping us raise funds and spread awareness of the cause.

We'd especially like to express our gratitude to Peter Kay for coming out of retirement to do a show in support of our very own Young Ambassador, Laura Nuttall. We'd also like to thank Tom Daley for his continued support and TikTok knitting antics.

We'd also like to thank Nicki Chapman for her continued support and championing of our work in the media, and for being a much-loved inspiration to so many other people affected by brain a tumour.

We, along with the entire community, were deeply saddened by the passing of Tom Parker in March 2022. We're so grateful for everything he and his loved ones did, and are continuing to do, to help improve the world for those affected by a brain tumour.

REACHING AND MOBILISING MORE VOICES FOR CHANGE

This year, we were delighted to significantly raise The Charity's profile by securing over 50% more media coverage compared to 2019/20. This has provided a boost in public awareness of the research we fund, the support services we provide, how we're campaigning for change and the ways we're raising money to help defeat brain tumours sooner.

We were so grateful to see over 400 people take action this year to become voices for change – including those personally affected by brain tumours, parliamentarians and celebrity supporters. Thanks to the amazing support take action to be voices for change on brain tumours.

Thanks to the incredible support we've received from our campaigners and Young Ambassadors, we were also able to host our first parliamentary drop-in event since the pandemic began. We shared key issues affecting the community with over 50 parliamentarians and were able to publically get their support.

A huge thank you to Tom, his wife Kelsey and his band members in The Wanted, for their generosity in gifting us £1 from every ticket sale to their Most Wanted UK tour – as well as to Jay, Max, Nathan, Siva,

everyone at The Wanted and Island Records and the song's writers and producers for generously donating all net proceeds for the first 12 months from sales of the single they released in Tom's memory – 'Forever Gold (for Tom)'.

And finally, our Head of Strategy, the indefatigable Clare Normand was honoured with an OBE this year for her work on behalf of The Alec Normand Fund and The Brain Tumour Charity.

MAKING SURE THE COMMUNITY'S VOICE IS PRESENT IN EVERYTHING WE DO

We now have over 1,300 people in our Involvement Network and through this group we're able to ensure the community's voice is present in everything we do. Led by 20 Involvement Champions, the Involvement Network have a say in helping us develop new services, resources, products and campaigns.

The absolute proof that everything we do is now driven by the community is that we've begun co-creating our entire new organisational strategy, *Beyond Brain Tumours*, as a community.

And we aren't just paying lip service to getting the community involved in developing the new strategy.

In fact, over 1,000 people have contributed so far, with a volunteer and staff team working group being guided by a steering group that includes those personally affected by a brain tumour, researchers, healthcare professionals and other brain tumour charities, including international charities.

"This idea for developing the strategy, an approach called 'Co-Creation', is a new and highly ambitious way to designing the path forward for The Charity.

It will be both challenging and, hopefully, extremely rewarding and successful. The Brain Tumour Charity has never tried this before – indeed, few organisations have – but it has the potential to be a very powerful process creating a strategy which the whole brain tumour community has contributed to, is aligned with and invested in."

Neil Munn

Involvement Champion and Co-Creator of *Beyond Brain Tumours*

BRINGING OUR TEAM BACK TOGETHER

In September 2021 we were able to hold our first full in-person Team Day for 18 months, which served as a fantastic opportunity to reconnect after so much time apart.

The aim of the day was to focus on the challenges facing the community, get the entire team involved with the development of our new strategy and get us all thinking about the role we're going to play in driving future change.

We were delighted to be joined by a diverse mix of speakers from the community, including those living with a brain tumour, carers and healthcare professionals.

Feedback from the event has been overwhelmingly positive, with over 95% of the team reporting feeling motivated and inspired as a result of attending.

“

It was so good to come together as a team, cement why we do what we do and celebrate our achievements.



MAKE IT COUNT

Due to the impact of the pandemic, we need to work even more efficiently, as a smaller and more adaptable charity.

We'll sustain our team culture and keep our commitment to defeating brain tumours by reallocating our time and resources – including streamlining the processes and technology we use.

HIGHLIGHTS OF 2021/22

ADAPTING TO A NEW NORMAL

Keeping our team connected to each other and the community during the pandemic was vital as we refused to slow down and compromise our mission of moving further, faster towards a world where brain tumours are defeated.

We take a huge amount of pride in our culture and connection with those we support, so it's fair to say there was a steep learning curve as we attempted to navigate the ever-changing lockdown restrictions.

By the end of 2021/22, we'd been able to settle into a new normal that embraced the hybrid nature of the post-pandemic workplace.

Our offices have been buzzing with creativity as a result of being able to collaborate in person again, but our time apart significantly improved our ability to work together remotely – setting us up for a bright future of teaming with international partners and making alliances with external organisations.

Our increased flexibility in offering more opportunities for staff to work remotely also means our team enjoys the best of both worlds and has allowed us to attract a wider range of talented individuals who may have previously shied away from commuting to our HQ five days a week.

In September 2021, we held our first annual Team Day event for 18 months, which was a great opportunity to spend time together after so much time apart and reflect on our progress to date. We dedicated a lot of time to hear from the community, learning about the experiences of those affected by brain tumours and understanding what's important to them.

It was a stark reminder of why we must continue to push for kinder treatments and, ultimately, a cure.

COMMERCIALISING BRIAN

Having invested in the technology and know-how that brings our BRIAN project to life, it became apparent this model would be valuable to other disease areas too. This provides a unique opportunity for The Charity to make a financial return on our investment, while also helping other communities affected by long-term illnesses.

Throughout 2021/22, The Charity has embarked in commercialising the technology underlying BRIAN (it's important to note that this does not include the data held within BRIAN) and has created new commercial trading subsidiary companies to do this. It's anticipated this new commercial venture will make a financial return and be a new income stream for The Charity within the next two years.

CELEBRATING OUR VOLUNTEERS

One of the things we're proudest of is the way we've grown involvement and volunteering during the pandemic.

In 2021, we were delighted to welcome our fourth cohort of Young Ambassadors to The Charity. They come from all over the UK and truly represent a diverse mix of experiences. Our Young Ambassadors embody our ethos of being a community-led charity. They're hopeful and determined and, like all our previous Young Ambassadors, will lead us forward and represent The Charity across campaigning, influencing, fundraising, support and research.

1,000+

volunteers lending their time, experience and expertise

Our team of volunteers help with everything from fundraising and spreading awareness of the signs and symptoms of a brain tumour in their local communities, to providing professional sports coaching for our London Marathon runners and quality checking the accuracy of our medical and scientific information – and so much more.

We simply couldn't have made the progress we have without them!



EMBRACING A NEW WAY OF FUNDING RESEARCH

Sadly, the COVID-19 pandemic meant that to be able to guarantee we could continue to fulfil our financial commitments to existing research projects, we were forced to pause our plans to fund new research through traditional grants funding.

This meant we needed to embrace a new way of funding if we were going to support pioneering new projects.

In August 2021, we launched an urgent fundraising appeal, calling upon everyone in the community to help us raise £450,000 to fund a first-of-its-kind clinical trial in the UK to investigate cannabinoids as a treatment for people with recurrent glioblastoma (GBM).

£450,000

raised in our cannabinoids appeal

Supported by generous major donors through The Big Give's matched-funding platform, and boosted by major national and international press coverage of our social media campaign (which featured over 50 members of our community), we were able to raise an incredible £139,311 in just one week!

We were then able to raise the additional funds required thanks to the support of the public and global research community, including a generous donation of £45,000 from Leeds Hospitals Charity.

Thanks to this new way of raising funds for research, the trial has been approved and will begin recruiting over 230 patients at 15 NHS hospitals across all UK nations in summer 2022.

"We are delighted to announce that, thanks to the support and generosity of so many in the community, the ARISTOCRAT trial will begin recruitment of patients in summer 2022.

"We know there has been significant interest among patients and researchers alike for some time about the potential activity of cannabinoids in treating glioblastomas. We're really excited that

this world-first trial here in the UK could help accelerate these answers and are so grateful to everyone who has donated to help us make this study possible – thank you.

"We'd also particularly like to thank Leeds Hospitals Charity for their significant contribution, which will enable up to 25 patients to access the trial at Leeds Teaching Hospitals.

"The recent early-stage findings were really promising and we now look forward to understanding whether adding Sativex to chemotherapy could help offer life-extension and improved quality of life, which would be a major step forward in our ability to treat this devastating disease."

Dr David Jenkinson, Chief Scientific Officer
Past Interim CEO (Jan 2021 – Jan 2022).

LEANING IN TO OUR RESPONSIBILITY FOR EQUALITY, DIVERSITY AND INCLUSION

We recognise that we have an important role in creating a fairer society and acknowledge that we, like many other charities, still have much work to do to ensure we're inclusive and representative of the communities we serve.

To help address this, we've begun to critically evaluate how inclusive and diverse we are as an organisation and developed an action plan that demonstrates our commitment to equality, inclusion and rooting out discrimination in all its forms.

To support this we established an Equality, Diversity and Inclusion working group, comprised of team members from across The Charity and with two team members acting as the Leads for driving forward our action plan. To keep us accountable for our progress we've also established a new Trustee Committee for Equality, Diversity and Inclusion.

EXCEPTIONAL RE-APPOINTMENT OF TRUSTEES

The pandemic has created a unique set of pressures for individuals and organisations throughout the world and The Charity is no exception. It also coincided with the departure of the CEO after ten years of dedicated service and a number of trustees reaching the end of their terms in office. After careful consideration by The Charity's Board, following a rigorous appraisal and in accordance with The Charity's constitution, in September 2021 The Board decided to extend the term by one year of two trustees, Berrie Norton and Graham Lindsay. Graham Lindsay subsequently resigned 30/06/2022 to assist the Interim CEO and leadership team.

Berrie Norton has had a long term involvement in the Support and Information Committee and a role in the recruitment of a new CEO. Graham Lindsay sat on the Remuneration and Governance and Ethics Committees. He also was a Co-Vice Chair and his reappointment provided valuable stability. The Board believed the continuity provided by extending their terms by one year beneficial to supporting The Charity.



FINANCE REVIEW

The global pandemic, which had a severe impact on The Charity's finances and activities throughout 2020-21, began to ease in the year to March 2022, allowing The Charity to return to growth.

The speed of growth combined with the remarkable generosity of the community resulted in income growing 38% to £11.5m, the highest income ever achieved by The Charity.

Total expenditure fell in the financial year compared to the previous year. This was due to the time it takes to recruit and scale back up operations following the pandemic.


INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year income was up year-on-year in most areas but there were a few notable items.

The ending of social distancing and restrictions on mass gatherings has permitted face-to-face events to happen once more. Accordingly, income from events such as marathons, cake sales and corporate fundraisers more than doubled year-on-year - rising by £1.2m.

Income from Major Gifts and Appeals were also substantially up, with the most notable item being £450k raised to fund a first-of-its-kind clinical trial in the UK to investigate cannabinoids as a treatment for people with recurrent glioblastoma (GBM).

The Charity also applied for and was successful in receiving £471k from a £20m fund from the Medical Research Council. The UK Government Covid Medical Research Charity Support Fund was established to assist charities funding medical research impacted by the COVID-19 pandemic.



EXPENDITURE

Expenditure in the year reduced by £0.7m to £10.6m. The reduction was in all areas of Charitable Activities and was due to the lasting effects of the pandemic.

The Charity's primary objective is to fund quality research and over half our expenditure is in this area as it is vital to achieving our ambitious objectives. Expenditure on research declined £0.4m due to research projects running behind schedule during the pandemic which has required rebudgeting of the timing of grants.


Patient support and campaigning and awareness expenditure also declined year-on-year. This was primarily due to lower salary costs after the size of the team significantly decreased in 2021/22 in response to financial impact of the pandemic and the time it takes to recruit and grow the team again. In 2021/22 the average number of employees in The Charity was 86 compared to 108 in 2020/21.

Fundraising expenditure increased £0.1m (7%) over the prior year. The primary driver of the increase is the cost of physical events taking place once again and reflects the 38% increase in income. This has off-set lower salary costs year-on-year as the average number of people in our Fundraising team also declined year-on-year in response to the pandemic.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. In the year to 31 March 2022 we managed to spend 82p as we continued our investment in quality research.

The Charity has a trading subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £41k which is to be donated to The Charity.

The Charity also formed two new subsidiaries, Acquist Data Holdings Limited and Acquist Data Limited in March 2022 which were dormant.



INVESTMENTS AND CASH

The COVID-19 pandemic caused considerable volatility in world-wide stock markets and this was compounded by the Russian invasion of Ukraine in February 2022. At the end of the financial year The Charity's investments were valued at £14.5m, a fall of £0.1m over the previous year.

All investments are held in highly liquid assets. Current forecasts do not expect the investments to need to be liquidated in the next twelve months as short-term volatility in values is not considered a significant risk.

Cash held as at 31 March 2022 was £5.2m.

RESERVES POLICY

The Charity's funds have recovered to their pre-pandemic levels, ending the financial year to 31 March 2022 at £7.6m.

The Charity maintained Unrestricted Funds of at least six months' operational costs to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments. The annual operational cost is about £6.7m. The level of Total Funds at 31 March 2022 was £7.6m, consisting of Unrestricted General Reserves of £2.7m, Designated of £1.7m and Restricted of £3.3m. After deducting the value of functional fixed assets £282k, Free Reserves available are £2.4m.

The Restricted and Designated Reserves are earmarked for use in the next two financial years. As a result of COVID-19, The Charity's Reserves Policy until 31 March 2023 is to have Total Reserves in excess of six months' operational costs. As at 31 March 2022, the actual cover was 13.6 months.

At 31 March 2022, we had unaccrued but committed research expenditure totalling £8.3m which was subject to satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2022 (which are all liquid) were £19.8m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Smith & Williamson have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £14.5m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash.

In a volatile year for investments due mostly to COVID-19 and the Russian invasion of Ukraine, the portfolio generated income of £325k and a valuation loss of £97k. In addition to managed investment funds, the Trustees decided in the year to invest in commercialising the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. The Charity has formed new subsidiaries for this commercial venture and evaluates any investments being made on its financial return against an equivalent asset class.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience,

pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across The Charity is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have over 1,000 active volunteers across the UK who support a wide range of different roles across The Charity. Voluntary activities include supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

1. That we fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.

2. That we are not able to commission enough high-quality research projects. We are developing our engagement with the brain tumour research community and working to build capacity in the sector. We are also looking at alternative research models. In addition, we have extended funding globally and put significant emphasis on building relationships with key researchers.

3. That we become affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective talent and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.

4. That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

5. That we are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres and ensure that we have leading-edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have a cyber insurance policy.

6. That we are impacted by a global pandemic, just like COVID-19. We have an incident management plan and this was implemented in March 2020, with the priority of helping those most vulnerable in the community to deal with the anxiety and practicalities caused by the pandemic. We have set up The Charity so that everyone can work from home, we have introduced virtual fundraising activities and have been able to furlough staff members if necessary. By having a six months' reserve policy we should be able to ride out any significant adverse financial impact on The Charity.

GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The COVID-19 pandemic impacted The Charity's community, finances and activities but as the restrictions associated with the pandemic have reduced or ended The Charity has adapted and returned to growth. Income has recovered more swiftly than expected although the financial outlook remains uncertain given the cost-of-living pressures in the global economy.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments. The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

OBJECTIVES FOR 2022-23

The Charity objectives remain aligned to its core values and our priority objectives for the year are:

- We will drive the **Best Care Everywhere** across the UK, driving up the quality of treatment centres in the UK and empowering our community to share their experiences.
- We will mobilise **Voices for Change**, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.
- We will harness the **Power of Data** to accelerate research, tackle inequality, empower choices, inform change and maximise our impact.

In addition:

- We will continue identifying the best global research to be funded through a new round of research grant funding
- We will complete and adopt our entirely new organisational strategy, *Beyond Brain Tumours* that we're co-creating as a community.
- We will start to see a financial return from the commercialisation of the intellectual property and technology underlying BRIAN (Brain tumouR Information and Analysis Network) – this does not include the data held in BRIAN.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. We are investing time and effort on expanding our fundraising to grow and to provide income for years to come, money that will be used to fund our ambitious year-on-year investment in the best global research.

Our new strategy that we are forming as a community in 2022-23 will guide our direction and the charity we need to become in future years.

THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research and began funding new projects again, as well as raising awareness and supporting thousands of people affected by a brain tumour.

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we cannot thank you enough for continuing to help us as we strive to defeat brain tumours!

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

BBC Children in Need
St James's Place Charitable Foundation
The AOK Trust
The Colin Oliphant Charitable Trust
The Julia and Hans Rausing Trust
The Syncona Foundation
The William Brake Foundation

FAMILY-LED CHARITY PARTNERS

Evie's Gift
James Clifford Campling Trust
Naseem's Manx Brain Tumour Charity
Nick's Fund
The Billie Butterfly Fund
The Brian Cross Memorial Trust
The Jake McCarthy Foundation
The Oli Hilsdon Foundation
Stay Strong Stu

CORPORATES

Allports Group
Atrato Capital Limited
BECG Group
Benesys
Bluecube Technology Solutions
Childs Farm
Clicky Media
CMC Markets
Federated Hermes
IHS Markit
JM Finn
John R. Adam & Sons
Knight Security Group
K&L Gates
Majestic Wine
Microsoft
Runningman Two
Salesforce
Thunderhead
Underbelly

CO-FUNDING PARTNERS

Action Medical Research
Cancer Research UK
Children with Cancer UK
Great Ormond Street Hospital
Children's Charity

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE
Charly Clive
Dominic Matteo
Earl Spencer
Ella and Matt Mills (Deliciously Ella)
Guy Opperman MP
Hal Cruttenden
Holly Matthews
Ian Chillcott
James Jordan
Jason Durr
Jess Mills
Jonny Wilkinson CBE
Lewis Moody OBE and Annie Moody
Liam Conlon
Lorraine Kelly OBE
Marc Silk
Matt Allwright
Mel Giedroyc
The Neales
Nick Baines (Peanut – Kaiser Chiefs)
Nicki Chapman
Olivia Colman CBE
Owain Arthur
Philippa Forrester
Phil Spencer
Russell Watson
Sandy Lyle MBE
Sherrie Hewson
Sian Reese-Williams
Steve Backshall
Tchéky Karyo
Tim Burgess and The Charlatans
Tom Daley
The Wanted

We'd also like to thank the actress and writer Dawn French, one of The Charity's first patrons and friend of Angela and Neil Dickson. Dawn has supported The Charity for over 20 years and continues to offer auction prizes and practical support wherever possible.

TRUSTEES AND GOVERNANCE

TRUSTEES

Jack Morris CBE (Chair)
Neil Dickson MBE (Vice Chair)
Graham Lindsay (resigned 30/06/2022)
Dr. Elena Bechberger
Dr. Rachel Edgar
Simon Hay
Sean Hird
Justine McIlroy
Philippa Murray
Berendina Norton
Graham Norton (resigned 03/07/2022)
Professor Alan Palmer
Beth Worrall
Anna Jarvis (appointed 16/06/2022)
Caroline Steel (appointed 16/06/2022)
Hayley Conroy (appointed 16/06/2022)
Jessica Sass (appointed 16/06/2022)
Dr Kieran Palmer (appointed 16/06/2022)
Matimba Swana (appointed 16/06/2022)
Dr Russell Hagan (appointed 16/06/2022)
Sukhdip Sandhu (appointed 16/06/2022)

The directors and trustees had liability insurance during the financial year.

PRESIDENT

Professor Sir Colin Blakemore
(passed away 27/06/2022)

CHIEF EXECUTIVE OFFICER

David Jenkinson (Interim CEO appointed 01/04/2021, resigned 24/01/2022)
Alex Lochrane (appointed 24/01/2022, resigned 01/07/2022)
Graham Norton (Interim CEO appointed 04/07/2022)
Graham Lindsay (Deputy-Interim CEO appointed 04/07/2022)

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP Centrum House, 36 Station
Road, Egham, Surrey TW20 9LF

BANKERS

Lloyds Bank Plc, 147 High Street,
Guildford, GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon
Smith and Williamson, 25 Moorgate, London

RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory Board (mentioned on page 36), these are just some of the researchers providing an ongoing contribution to our success.

Adam Waldman
Adel Samson
Alex Bullock
Andrew Peet
Anthony Byrne
Anthony Chalmers
Antony Michalski
Barry Pizer
Catherine McBain
Chris Jones
Colin Kennedy
Colin Watts
Conor Mallucci
Darren Hargrave
David Jones
David Walker
Denise Sheer
Diane Puccetti
Eric Aboagye
Federico Roncaroli
Filomena Maggino
Gelareh Zadeh
Gregor Hutter
Ian Waddell

Jan Schuemann
Michael Taylor
Michael Vogelbaum
Monika Hegi
Neil Carragher
Ola Rominiyi
Olivier Ayrault
Pamela Kearns
Paul Brennan
Paul Northcott
Paula Croal
Petra Hamerlick
Phedias Diamandis
Philipp Euskirchen
Pim French
Rameen Beroukhim
Richard Gilbertson
Roel Verhaak
Roger Packer
Russ Hagen
Sebastian Brandner
Sébastien Serres
Siddhartha Mitra
Simon Bailey
Simona Parrinello
Sophie Thomas
Spencer Watson
Stefan Pfister
Steve Pollard
Steven Clifford
Stuart Allan
Stuart Smith
Susan Short
Terri Armstrong
Thomas Würdinger
Todd Hankinson
Tyler Miller
Verónica Rendo
Victor Levin
Vincenzo D'Angiolella



BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Richard Gilbertson
Professor Steve Clifford
Dr Mark Gilbert
Dr David Adams
Dr Susan Chang
Dr Cynthia Hawkins
Dr Paul Northcott
Professor Simona Parrinello
Professor Colin Watts
Dr Duane Mitchell
Professor Rick Livesey
Dr Marcel Kool
Dr Lucy Stead
Dr Gerry Thompson

INSTITUTION

The Cambridge Cancer Centre, UK
The Institute of Child Health, Newcastle University, UK
National Institutes of Health (NIH), USA
The Wellcome Trust Sanger Institute, UK
University of California San Francisco, USA
The Hospital for Sick Children, Canada
St Jude Children's Research Hospital, USA
University College London (UCL), UK
University of Birmingham, UK
University of Florida, USA
German Cancer Research Centre, Germany
University of Leeds, UK
University of Edinburgh, UK

PAEDIATRIC LOW GRADE CENTRE SAB

NAME

Dr Nick Foreman
Dr Paola Scaffidi
Dr Anat Stemmer-Rachamimov
Professor Martin van den Bent
Dr Christian Dillon
Professor David Ashley
Dr Floris Barthel

INSTITUTION

Children's Hospital Colorado, Denver, USA
Francis Crick Institute, London, UK
Massachusetts General Hospital
Erasmus MC Cancer Center, The Netherlands
PhoreMost Ltd, Cambridge, UK
Duke Cancer Institute, USA
Translational Genomics Institute, Phoenix, USA

LAY ADVISORS

Ms Christina Brincat
Mrs Deborah Crossan
Mrs Rachel Rathbone
Ms Louise Webber-Edwards
Mr John Graham

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees who are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed on page 34.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 8 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion

- Remuneration
- Technology Commercialisation
- Databank (BRIAN)

The Charity has formed two Scientific Advisory Boards (SABs) to ensure we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the Paediatric Low Grade Centre Scientific Advisory Board (Paediatric Low Grade Centre SAB) can be found on page 36.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and support the diverse community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort and raising awareness, as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our new research strategy 'Accelerating a Cure' launched in 2021-22 as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers.



We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research & Databank Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all our fundraising activity. We did not engage with any third-party fundraisers during the year. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard

applicable in the UK and Republic of Ireland. Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 15 September 2022 and signed on their behalf by:


Jack Morris CBE
Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2022 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2022 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with

the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.
- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
 - Posting of fraudulent journal entries
 - Posting of fraudulent payments and receipts in the accounting software
 - Authorisation, processing, and payment of fraudulent expenses
 - Fictitious employees
 - Timing of revenue recognition
- Audit procedures performed by the engagement team included:
 - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
 - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
 - Challenging assumptions and judgments made by management in its significant accounting estimates; and


- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Janice Matthews
FCA (Senior statutory auditor)
for and on behalf of
Menzies LLP
Chartered Accountants
Statutory Auditor
Centrum House
36 Station Road
Egham
Surrey
TW20 9LF

Date: 15-09-2022

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2022 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2021 £'000
Income and expenditure							
Income from:							
Donations and legacies	3	8,681	2,276	10,957	6,577	1,180	7,757
Other trading		161	32	193	171	15	186
Investments		325	-	325	355	-	355
Total income		9,167	2,308	11,475	7,103	1,195	8,298
Expenditure on:							
Raising funds		1,872	1	1,873	1,742	2	1,744
Charitable activities							
Research		4,038	2,172	6,210	5,405	1,239	6,644
Patient support		1,394	386	1,780	1,724	371	2,095
Campaigning & raising awareness		760	2	762	829	20	849
Total expenditure on charitable activities		6,192	2,560	8,752	7,958	1,630	9,588
Total expenditure	4	8,064	2,561	10,625	9,700	1,632	11,332
Net income before gains and losses on investment assets		1,103	(253)	850	(2,597)	(437)	(3,034)
Realised and unrealised gains on investment assets		(97)	-	(97)	2,656	-	2,656
Net income/(expenditure)		1,006	(253)	753	59	(437)	(378)
Transfers		-	-	-	(955)	955	-
Net movement in funds for the year		1,006	(253)	753	(896)	518	(378)
Reconciliation of funds							
Balances at 1 April 2021		3,348	3,509	6,857	4,244	2,991	7,235
Balances at 31 March 2022		4,354	3,256	7,610	3,348	3,509	6,857

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities.


The notes on pages 45-59 form part of these financial statements.

CONSOLIDATED BALANCE SHEET AT 31 MARCH 2022

Company number: 08266522

	Notes	Consolidated 2022 £'000	Consolidated 2021 £'000	Company 2022 £'000	Company 2021 £'000
Fixed assets					
Intangible assets	10	15	34	15	34
Tangible assets	11	267	281	267	281
Investment in subsidiaries	12	-	-	-	-
Investments	12	14,536	14,652	14,536	14,652
Current assets					
Stock		6	9	-	-
Debtors	13	820	452	820	453
Cash at bank		5,240	4,978	5,239	4,972
		6,066	5,439	6,059	5,425
Creditors					
Amounts falling due within one year	14	(13,174)	(13,449)	(13,208)	(13,456)
Provision for liabilities	15	(100)	(100)	(100)	(100)
Net current (liabilities)/ assets		(7,208)	(8,110)	(7,249)	(8,131)
Total assets less current liabilities		7,610	6,857	7,569	6,836
Funds					
General reserve		2,662	1,752	2,621	1,731
Designated funds		1,692	1,596	1,692	1,596
Unrestricted funds		4,354	3,348	4,313	3,327
Restricted funds		3,256	3,509	3,256	3,509
	19	7,610	6,857	7,569	6,836

The financial statements were approved by the trustees on 15 September 2022 and signed on their behalf by:


 Jack Morris CBE
 Chair of Trustees


 Beth Worrall
 Chair of Finance Committee

The notes on pages 45-59 form part of these financial statements.

CONSOLIDATED CASH FLOW FOR THE YEAR ENDED 31 MARCH 2022

	2022 £'000	2021 £'000		
<u>Reconciliation of net income to net cash flow from operating activities</u>				
Net income for the year	753	(378)		
Adjustments for:				
Depreciation	42	50		
Losses/ (gains) on investments	97	(2,619)		
Income from investments	(325)	(355)		
Provision for liabilities	-	100		
Loss/ (profit) on sale of fixed assets	-	2		
(Increase)/ decrease in stocks	2	2		
Decrease/ (increase) in debtors	(367)	268		
Increase / (decrease) in creditors	(274)	541		
Net cash (used in)/ provided by operating activities	(72)	(2,388)		
	2022 £'000	2021 £'000		
<u>Statement of cash flows</u>				
Cash flows from operating activities				
Net cash (used in)/ provided by operating activities	(72)	(2,388)		
Cash flows from investing activities:				
Dividends, interest and rents from investments	325	355		
Purchase of computer software	-	-		
Purchase of property plant & equipment	(10)	(296)		
Sale/(purchase) of investments	19	-		
Net cash provided by/ (used in) investing activities	334	59		
	2022 £'000	2021 £'000		
Change in cash and cash equivalents in the year	262	(2,328)		
Balances at 1 April 2021	4,978	7,306		
Balances at 31 March 2022	5,240	4,978		
	2022 £'000	2021 £'000		
<u>Analysis of cash and cash equivalents</u>				
Cash in hand	5,240	2,944		
Notice deposits (less than 3 months)	-	2,034		
Total cash and cash equivalents	5,240	4,978		
	At 1 April 2021	Cash from sale of investments	Other Cash flows	At 31 March 2022
<u>Analysis of changes in net debt</u>				
Cash	2,944	19	2,277	5,240
Cash equivalents	2,034	-	(2,034)	-
Net debt	4,978	19	243	5,240

NOTES TO THE FINANCIAL STATEMENTS

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 35. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. Accounting policies

(a) Basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £733,000 (2021: outgoing £394,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) **Company status**

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 34. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) **Income**

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) **Expenditure**

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

(e) **Stocks**

Stock is measured at the lower of cost and net realisable value.

(f) **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) **Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) **Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) **Investments**

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) **Donated assets and services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) **Operating lease**

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) **Pensions**

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) **Financial instruments**

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) **Going concern**

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The COVID-19 pandemic began to impact in March 2020 and continued to affect this financial year but with diminishing impact as the year went on and restrictions in the UK eased. The Charity’s income through fundraising from mass participation events or the holding of physical fundraising events started to return as the year went on. Similarly, daily activities of The Charity with employees working remotely shifted to a hybrid working model. Financial investments continued to be volatile as financial markets reacted to global events. The Charity demonstrated it can adapt to these changes and has returned to growth. This growth is expected to continue in the next twelve months and beyond.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. Donations and legacies

	Unrestricted	Restricted	2022	Unrestricted	Restricted	2021
	£'000	£'000	Total £'000	£'000	£'000	Total £'000
Ordinary activities:						
Regular giving	308	39	347	258	41	299
Donations, appeals and fundraising	6,756	1,949	8,705	5,352	1,120	6,472
Gift aid	815	45	860	483	19	502
Legacies	273	243	516	155	-	155
Government grants	529	-	529	329	-	329
	8,681	2,276	10,957	6,577	1,180	7,757

Government grants consist of amounts received under the Government Coronavirus Job Retention Scheme and the COVID Medical Research Charity Support Fund.

4. Analysis of resources expended

	Direct Costs £'000	Grants £'000	Support Costs £'000	2022 Total £'000
Raising funds	1,721	-	152	1,873
Charitable activities:				
Research	1,085	5,079	46	6,210
Patient support	1,706	-	74	1,780
Campaigning and raising awareness	675	-	87	762
Total expenditure on charitable activities	3,466	5,079	207	8,752
Total expenditure	5,187	5,079	359	10,625

	Direct Costs £'000	Grants £'000	Support Costs £'000	2021 Total £'000
Raising funds	1,579	-	165	1,744
Charitable activities:				
Research	1,167	5,446	31	6,644
Patient support	2,019	-	76	2,095
Campaigning and raising awareness	769	-	80	849
Total expenditure on charitable activities	3,955	5,446	187	9,588
Total expenditure	5,534	5,446	352	11,332

5. Research grant cost analysis

	2022 £'000	2021 £'000
Research programmes	3,640	4,406
Research projects	1,145	831
Clinical trials	299	155
Fellowships	-	54
Conferences	(5)	-
	5,079	5,446

A breakdown of research costs by individual award is provided in note 22.

6. Support costs by activity

	Finance and human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	44	25	44	11	28	152
Charitable activities:						
Research	13	7	14	4	8	46
Patient support	21	12	22	6	13	74
Campaigning and raising awareness	25	14	25	7	16	87
2022 Total	103	58	105	28	65	359

	Finance and human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	54	19	37	17	38	165
Charitable activities:						
Research	10	4	7	3	7	31
Patient support	25	9	17	8	17	76
Campaigning and raising awareness	26	9	19	8	18	80
2021 Total	115	41	80	36	80	352

7. Governance costs

	2022 £'000	2021 £'000
Auditor's remuneration	15	20
Legal and professional fees	-	3
Staff	50	57
	65	80

In addition to Auditor's remuneration for audit shown above, a further £4,500 was paid for accounting and tax advice. Trustees received no remuneration (2021: £nil). Trustees received no reimbursement for travel expenses in the year totalling £nil (2021: one for £26). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2021: £nil).

8. Staff costs

	Group		Company	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Wages and salaries	2,776	3,402	2,776	3,402
Social security costs	223	311	223	311
Payments to defined contribution pension plans	223	296	223	296
	3,222	4,009	3,222	4,009

During the year redundancy payments were made totalling £nil (2021: £29,000). At 31 March 2022 there was £nil provided (2021 £nil).

The average number of employees during the year was 86 (2021: 108).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2022	2021
£60,001 - £70,000	2	1
£70,001 - £80,000	1	1
£80,001 - £90,000	1	1
£90,001-£100,000	-	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £453,000 (2021: £572,000).

9. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. Intangible fixed assets

Group and Company

	Computer Software £'000
Cost	
At 1 April 2021	161
Additions	-
At 31 March 2022	161
Depreciation	
At 1 April 2021	128
Charge for the year	18
At 31 March 2022	146
Net book value	
At 31 March 2022	15
At 31 March 2021	34

11. Tangible fixed assets

Group and Company

	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2021	289	168	457
Additions	3	6	9
At 31 March 2022	292	174	466
Depreciation			
At 1 April 2021	14	161	175
Charge for the year	19	4	24
At 31 March 2022	34	165	199
Net book value			
At 31 March 2022	258	9	267
At 31 March 2021	274	7	281

12. Investments

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2021	100
Additions	100
At 31 March 2022	200

On 3 March 2022 The Charity formed a new subsidiary Acquist Data Holding Limited. The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holding Limited, a dormant company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Limited owns 100% of Acquist Data Limited, a dormant company incorporated in England and Wales, company number 13951572

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2022 the aggregate of the share capital and reserves of TBTC Trading Ltd was £21,000 (2021: £21,000).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2022 £'000	2021 £'000
Turnover	59	49
Cost of sales	(15)	(12)
Gross profit	44	37
Other operating expenses	(3)	(16)
Profit before donation	41	21
Donation	(21)	(4)
Retained profit/ (loss)	20	17

Cost of sales represent cost of stock sold in the year.

At 31 March 2022 the aggregate assets of TBTC Trading Ltd were £45,000 (2021: £24,000), aggregate liabilities £4,000 (2021: £3,000) and shareholder's funds £41,000 (2021: £21,000).

(b) General investments

	2022 £'000	2021 £'000
Group and Company		
At 1 April	14,652	12,033
Additions at cost	635	1,464
Disposals	(533)	(4,541)
Net unrealised (loss) on revaluation	(218)	5,696
At 31 March	14,536	14,652
Historical cost	12,306	12,204
	2022 £'000	2021 £'000
Investments at market value comprised:		
UK equities	3,236	3,775
Overseas equities	3,679	3,539
Absolute return funds	418	442
Property	124	-
Multi asset funds	509	234
Alternative investments	287	578
Fixed income securities	3,421	3,184
Cash held within the investment portfolios	2,862	2,900
Accrued income	-	-
At 31 March	14,536	14,652

During the year income from listed investments was £324,000 (2021: £350,000) and interest on deposits £1,000 (2021: £4,000).

13. Debtors

	Consolidated		Company	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Trade debtors	373	74	373	74
Accrued income and prepayments	446	353	446	353
Other debtors	1	26	1	26
Amounts owed by TBTC Trading Ltd	-	-	-	-
	820	453	820	453

14. Creditors

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2022 £191,000 (2021: £297,000) of income was deferred and £357,000 (2021: £97,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Grants payable	12,650	12,293	12,650	12,294
Accruals and deferred income	381	468	378	465
Trade creditors	38	593	38	593
Other creditors	28	28	28	28
Social security and other taxes	77	67	76	67
Amounts owed to TBTC Trading Ltd	-	-	38	9
	<u>13,174</u>	<u>13,449</u>	<u>13,208</u>	<u>13,456</u>

15. Provision for liabilities

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
At 1 April 2021	100	-	100	-
Additions	-	100	-	100
Disposals	-	-	-	-
At 31 March 2022	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>

The provision related to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. Research commitments

At 31 March 2021 The Charity had authorised commitments that were subject to outstanding conditions amounting to £8,254,000 (2021: £13,586,000), these are expected to fall due as follows:

	2022	2021
	£'000	£'000
Within one year	3,712	5,736
Between one and two years	2,768	3,609
Between two and three years	1,361	2,546
Between three and four years	134	1,283
Between four and five years	134	133
Five years and further	145	279
	<u>8,254</u>	<u>13,586</u>

The above commitments will be funded from reserves and future income.

17. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Within one year	301	143	301	143
Between one and five years	<u>1,182</u>	<u>1,242</u>	<u>1,182</u>	<u>1,242</u>
	<u>1,483</u>	<u>1,385</u>	<u>1,483</u>	<u>1,385</u>

Operating lease charges during 2022 were £57,000 for property (2021: £30,000).

18. Analysis of net assets between funds

	Unrestricted Funds	Restricted Funds	Total 2022
	£'000	£'000	£'000
Intangible fixed assets	15	-	15
Tangible fixed assets	267	-	267
Investments	14,536	-	14,536
Other current assets	(887)	6,953	6,066
Current liabilities	<u>(9,577)</u>	<u>(3,697)</u>	<u>(13,274)</u>
	<u>4,354</u>	<u>3,256</u>	<u>7,610</u>

	Unrestricted Funds	Restricted Funds	Total 2021
	£'000	£'000	£'000
Intangible fixed assets	34	-	34
Tangible fixed assets	281	-	281
Investments	14,652	-	14,652
Other current assets	(1,572)	7,011	5,439
Current liabilities	<u>(10,047)</u>	<u>(3,502)</u>	<u>(13,549)</u>
	<u>3,348</u>	<u>3,509</u>	<u>6,857</u>

19. Funds

Consolidated	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:						
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	<u>3,509</u>	<u>2,309</u>	<u>(2,562)</u>	<u>-</u>	<u>-</u>	<u>3,256</u>
Unrestricted funds:						
General reserve	1,752	8,112	(7,105)	-	(97)	2,662
Designated funds	1,596	1,054	(958)	-	-	1,692
	<u>3,348</u>	<u>9,166</u>	<u>(8,063)</u>	<u>-</u>	<u>(97)</u>	<u>4,354</u>
	<u>6,857</u>	<u>11,475</u>	<u>(10,625)</u>	<u>-</u>	<u>(97)</u>	<u>7,610</u>
Company	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:						
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	<u>3,509</u>	<u>2,309</u>	<u>(2,562)</u>	<u>-</u>	<u>-</u>	<u>3,256</u>
Unrestricted funds:						
General reserve	1,731	8,053	(7,087)	21	(97)	2,621
Designated funds	1,596	1,054	(958)	-	-	1,692
	<u>3,327</u>	<u>9,107</u>	<u>(8,046)</u>	<u>21</u>	<u>(97)</u>	<u>4,313</u>
	<u>6,836</u>	<u>11,416</u>	<u>(10,607)</u>	<u>21</u>	<u>(97)</u>	<u>7,569</u>

Consolidated	At 1 April 2020 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,499	6,244	(8,693)	(955)	2,656	1,752
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,243</u>	<u>7,103</u>	<u>(9,700)</u>	<u>(955)</u>	<u>2,656</u>	<u>3,348</u>
	<u>7,235</u>	<u>8,297</u>	<u>(11,332)</u>	<u>-</u>	<u>2,656</u>	<u>6,857</u>
Company	At 1 April 2020 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,495	6,195	(8,665)	(950)	2,656	1,731
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,239</u>	<u>7,054</u>	<u>(9,672)</u>	<u>(950)</u>	<u>2,656</u>	<u>3,327</u>
	<u>7,230</u>	<u>8,248</u>	<u>(11,303)</u>	<u>4</u>	<u>2,656</u>	<u>6,836</u>

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 22.
Everest fund	During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2022 The Charity owed TBTC Trading Ltd £37,933 (2021: £9,444).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited. Acquist Data Holdings Limited and Acquist Data Limited were dormant in the financial year. At 31 March 2022 The Charity owed Acquist Data Holdings Limited £100 (2021: £nil).

Trustees, their close family members and entities they control, made donations to The Charity totalling £41,336 during the year (2021: £16,783) and paid contributions totalling £381 (2021: £nil) during a number of our fundraising events.

21. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated to specific areas of activity as follows:

Trust and foundation	£'000	Charitable activity
Albert Gubay Charitable Foundation	141	Restrict fund for Research

22. Research awards

	2022 £'000	2021 £'000
Programme - Chesler - ICR - Medullo super enhancers	308	306
Programme - Pollard - University Edinburgh - Chromatin targets in GBM	-	317
Programme - Jones - DKFZ - Everest Centre	914	945
Programme - Kennedy - University Southampton - PNET5 QoL	45	43
Programme - Wurdinger - VU Amsterdam - WINDOW	-	387
Programme - Zadeh - University Health Network - Clinically aggressive meningiomas	130	300
Programme - Northcott - St Jukes - MERIT	130	291
Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma	267	216
Programme - Parrinello - UCL - Mapping spatio-temporal heterogeneity	357	339
Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC	299	238
Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM	564	578
Project - Edinburgh - Brenan	-	(73)
Project - Development of a novel tumour-targeting thermogel activated by Matrix Metalloproteinases	-	(7)
Project - Clark - UCL Neurocognitive effects of medullo	-	(73)
Project - Kennedy - University Southampton - PROMOTE	-	(22)
Project - Rooney - University Edinburgh - BT LIFE	-	(28)
Project - Sharp - Newcastle University - Self-supporting management for survivors	111	-
Project - Northcott - St Jukes - Refining medullo in USA clinical trials	100	100
Project - van den Bent - Erasmus Medical Centre - Refining glioma classification in CATNON trial	-	18
Project - Taphoorn - Leiden University Medical Centre - Defining patient reported outcomes	-	43
Project - Hawkins - Uni Birmingham - Combining child and young adult data for better monitoring	18	140
Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people	82	-
Project - Schuemann - Massachusetts General Hospital - Extreme dose rate proton therapy	-	56
Project - Hegi - Lausanne - MGMT methylation	42	-
Project - Smith - Nottingham - RNA methylation	-	60
Project - Rominiyi - Sheffield - Ex-vivo 3D models	60	-
Clinical Trial - Kearns - University Birmingham - PNET5 CTU	44	44
Clinical Trial - HR-MB - Bailey - Newcastle	109	111
Clinical Trial - ARISTOCRAT - Short - Leeds	146	-
Fellowship - Bihannic - St Jude - Origins of Groups 3 and 4 medullo	-	54
Programme - Quest for Cures 2019 - Chesler ICR	296	338
Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber	329	195
Project - Clinical Biomarkers 2019/2 - Zadeh - UHN	207	96
Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital	96	101
Project - Expanding Theories 2019/2 - French - Erasmus	60	60
Project - Expanding Theories 2019/2 - Brandner - UCL	58	56
Project - Future Leaders 2019 - Croal - Nottingham	66	36
Project - Future Leaders 2019 - Watson - Lausanne	60	60
Project - Future Leaders 2019 - Miller - Massachusetts	60	60
Project - Future Leaders 2019 - Rendo - Dana-Farber	60	60
Project - Quality of Life 2019 - Byrne - Cardiff	65	88
Conferences and workshops - Kennedy - Southampton	(5)	-
Other	-	(85)
	<u>5,079</u>	<u>5,446</u>

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2021.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).

The logo for The Brain Tumour Charity is displayed on a white, rectangular fabric patch with rounded corners. The text is in a bold, sans-serif font. "THE" is in small capital letters above "BRAIN". "BRAIN" is in large capital letters, with the "I" replaced by a thick red vertical bar. Below "BRAIN" is "TUMOUR" in large capital letters, with the "O" replaced by a solid red circle. At the bottom, "CHARITY" is in smaller capital letters.

**THE
BRAIN
TUMOUR
CHARITY**